Related Experiment Video

Updated: Nov 16, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.8K

Gait phase triggered deep brain stimulation in Parkinson's disease

Kenneth H Louie1, Chiahao Lu2, Tessneem Abdallah2

  • 1Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, 55455, United States.

Brain Stimulation
|February 21, 2021
PubMed
Summary

No abstract available in PubMed .

Keywords:
Closed-loopDeep brain stimulationGaitParkinson’s diseaseResponsive stimulation

More Related Videos

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

9.1K
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

15.1K

Related Experiment Videos

Last Updated: Nov 16, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.8K
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

9.1K
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

15.1K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

743
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
743
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K

Articles linked to this work by shared authors, journal, and citation graph.

Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy.

Epilepsia·2026

Motor evoked potentials as markers of internal capsule current spread during deep brain stimulation for Parkinson's disease.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026

A computationally efficient adaptive phase response curve estimator for real-time closed-loop neuromodulation.

Journal of neural engineering·2026

Adaptive deep brain stimulation for dynamic gait control in Parkinson's disease: a randomized feasibility trial.

Nature medicine·2026

Cortico-pallidal beta dynamics underlie impaired turning in Parkinson's disease.

NPJ Parkinson's disease·2026

Neural signatures of real-world turning during naturalistic locomotion in Parkinson's Disease.

medRxiv : the preprint server for health sciences·2026

Reduced Left vmPFC-STN-Related White Matter Integrity Is Associated with Pre-Surgical Apathy in Parkinson's Disease.

Brain stimulation·2026

Minimal reservoir computing generates hippocampal-inspired stimulation for open-loop modulation of cortical networks in vitro.

Brain stimulation·2026

A standardized, surgically relevant map for emergence of organ-specific branches from the human vagus nerve.

Brain stimulation·2026

Dose Dependent Effects of Transcranial Photobiomodulation on Blood-Oxygenation-Level-Dependent Power in Major Depressive Disorder.

Brain stimulation·2026

Cortical specificity matters: the importance of stimulating hindlimb representation for the recovery of skilled locomotion after severe spinal cord injury.

Brain stimulation·2026

Direct Substantia Nigra Deep Brain Stimulation in Parkinson's Disease: Efficacy, Safety, and the Frequency-Response Relationship.

Brain stimulation·2026

Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization.

Cureus·2026

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Frontiers in endocrinology·2026

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.

Canadian journal of kidney health and disease·2026

Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.

Frontiers in pharmacology·2026

Dynamic structural profiling of PINK1 mutations (T313M and L347P) reveals a vital molecular perturbation namely phospho-Serine 65 ubiquitin recognition point in mitophagy mediated autosomal recessive Parkinson's disease (ARPD).

Frontiers in molecular neuroscience·2026

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Therapeutic advances in neurological disorders·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us